Breast Cancer

Breast Cancer Quality Measures

Axillary Sentinel Lymph Node Biopsy Performed for Patients Receiving Surgical Treatment of Breast Cancer (N = 1931)

2020-2021

Cleveland Clinic's performance was 86% (771 of 901) in 2020 and 82% (848 of 1030) in 2021 for patients receiving surgical treatment of breast cancer.

Needle Core or Fine Needle Aspirate Biopsy Prior to Surgical Treatment of Breast Cancerᵃ (N = 2258)

2020-2021

ᵃData from Cleveland Clinic tumor registry for main campus and family health center locations.

Cleveland Clinic's performance was 96%% (1018 of 1065) in 2020 and 95% (1132 of 1193) for this Commission on Cancer standard of care quality measure (95% confidence interval [CI], 97.6-99.7). Cleveland Clinic performs within the acceptable range for biopsy to surgical treatment of breast cancer.

Breast Conservation Surgery Rate for Women With Clinical Stage 0, I, or II Breast Cancerᵃ (N = 2096)

2020-2021

CoC = Commission on Cancer

ᵃData from Cleveland Clinic tumor registry for main campus and family health center locations.

Cleveland Clinic's performance was 58%% (570 of 982 patients) in 2020 and 59% (653 of 1114 patients) in 2021 for this Commission on Cancer (CoC) standard of care quality surveillance measure (95% CI, 50.0%-59.0%). The CoC does not define a benchmark performance rate. The National Accreditation Program for Breast Centers standard is 50%. The rate at Cleveland Clinic reflects patient choice and referral bias of patients seeking surgery and reconstruction at Cleveland Clinic.

Median Time to Treatment for Breast Cancer Patients by Quarter

2017-2021

An initial diagnosis of cancer is a time when patients are often desperate for answers.¹ Reducing this stress and anxiety by ensuring patients begin treatment as quickly as possible is a Taussig Cancer Institute imperative. Using the Institute's Cancer Tumor Registry and propriety Cancer Data Warehouse, the difference between the date of first positive biopsy and the first day the patient received any cancer-related treatment is measured quarterly for all patients diagnosed with or treated for cancer at Cleveland Clinic's main campus or family health centers.

After median days to first treatment is calculated for all disease groups, the multidisciplinary teams work to increase access and improve efficiency to reduce the time to treatment. These intensive efforts to identify and solve institutional causes for treatment delays have reduced the median time to treatment initiation.